Nektar downgraded to Hold from Buy at Jefferies

theflyonthewall.com

Jefferies downgraded Nektar (NKTR) citing increased regulatory risks for opioid induced constipation after competitors Salix (SLXP) and Progenics (PGNX) last week disclosed FDA concerns. The firm lowered its price target for Nektar shares to $8 from $10.

Rates

View Comments (0)